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Abstract 
Background: As the most common cancer in male, prostate cancer makes up 9.5% of new 
cancer cases and 4.8% of all cancer death in US in 2018. Though the 5-year survival of 
prostate cancer is high and multiple treatments are available, the death rate of prostate cancer 
was still more than 19.5 per 100,000 men per year. With more and more evidence suggested 
that piRNA may play a more important role in tumorigenesis, we want to find out if piRNAs 
can be a potential treatment for prostate cancer.  
Method: Two Prostate cancer cell lines (PC3, LNCap) and a normal prostate cell line 
(WPMY-1) were either transfected with piR-021163 at treatment group or single-stranded 
random RNA sequence as negative control group. MTS, wound healing and colony formation 
assay were done after transfection to detect cancer cell proliferation, migration and 
anchorage-independent growth in vitro which are crucial for carcinogenesis. Total RNA from 
cells were also extracted for genome-wide expression profiling. The result of mRNA array 
was analyzed with IPA software to find gene expression level differences between piR-
021163 treated group and random RNA treated negative control group.  
Result: The result of in vitro test showed that ipR-021163 has different impact on different 
prostate cancer cell lines. In PC3 cells, it showed significant (p<0.001) decrease in cell 
proliferation (72h after transfection), migration (24h after transfection) and anchorage-
independent growth (after 2 weeks of transfection) when transfected with piR-021163 
protective allele comparing with negative control group. But no significant different was 
observed in the LNCap cell line. IPA analysis suggested that TNF might be a core 
functionally interrelated molecule in piR-021163 functional pathway. And transfection of 
piR-021163 may lead to the decrease of inflammation of body cavity. 
Conclusion: The role of piR-021163 in prostate cancer development and progression may be 
cancer subtype-specific. The cancer suppression effect of piR-021163 should be mediate 
through the activation TNF and is related with the inhibition of inflammation. 
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Tables and figures 
piR-021163 (protective allele) TAACCAATGGGCAAAGGTGATGGAATGTCACC 
piR-021163 (risk allele) TAACCAATGGGCAAAGGTGAGGGAATGTCACC 
Random control RNA UGAACGAAUAGCGGAAGCUAGGCCCC 
Table 1. RNA sequence of piR-021163 protective allele and risk allele. And RNA sequence of 
single-stranded random RNA used as negative control. 
 























PC3 cell proliferation assay to find effective dose
 
Figure 1. PC3 cell proliferation assay treated with protective allele piR-021163 concentration 
range from 10μM to 0.001μM or negative control RNA in 96-well plate. Proliferation was 
quantified with MTS assay at 0, 48, 72, 96 hours after transfection. Cell numbers are expressed 
as Mean ± SD, n = 9. 
 
 Inhibition ratio compare with negative control group 
Time 
(h) 
Experiment 1 Experiment 2 Experiment 3 
10μM 0.1μM 0.001μM 10μM 0.1μM 0.001μM 10μM 0.1μM 0.001μM 
48 36% 2% 12% 43% -3% 16% 28% -12% -12% 
72 41% -2% -3% 53% 9% 15% 41% -47% -38% 
96 44% 8% 11% 59% 15% 22% 50% 0% 4% 
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Figure 2. Cell viability assay with MTS. (A) In PC3 cells, piR-021163 at concentration of 10μM 
to 0.001μM or negative control RNA were used for transfection. (B) The most effective piR-
021163 concentration, 10μM, or negative control RNA was applied in PC3, LNCap and 
WPMY-1 cell lines. Cell viability was calculated with Equation 1 at 0, 48, 72, 97 hours of 















































Figure 3. Approximately, 3,000 PC3 cells were seeded per well on a 6-well plate with 2ml 
complete F-12 medium in triplicate. Cells were transfected with 10μM piR-021163 or 10μM 
negative control RNA 24 hours after seeding in single cell suspension. Cell colonies were 
formed and stained in 2 weeks. (A) Images of colonies formed in each treatment condition are 
shown. (B) Number of colonies were calculated under microscope *, P < 0.05; **, P < 0.01; 
***, P < 0.001; error bars denote SD of replicate experiments. 
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Figure 4. 24 hours after PC3 cell seeding (about 500,000 cells per well), either 10μM piR-
021163 protective allele or negative control RNA were used for cell transfection. Straight 
wounds were created with pipette tip. (A) Images of wounds were recorded at 0h, 8h, 24h, 32h 
and 48h after wound creation. (B) Wound size was quantified with the help of ImageJ. And 
healing rate was calculated with Equation 3. *, P < 0.05; **, P < 0.01; ***, P < 0.001; error 
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Figure 5. Expression affected by transfection of piR-021163 protective allele in PC3 were 
enriched for those with roles in the tumor cell apoptosis, cancer cell death, cancer cell 
movement and T lymphocytes recruitment according to IPA. P values were generated using 
Fisher's exact test to calculate a statistical significance of overlap of my gene with a particular 





Figure 6. (A) The most confident regulator factor affected by piR-021163 transfection. 
According to IPA, activation of TNF gene in the upstream (z-score=3.085, p-value=1.03*10-
11) and inhibition of inflammation (z-score=-2.007, p-value=3.23*10-5) is predicted to be 
significantly related with the transfection of piR-021163. (B) This Mechanistic network 
shows the interactions between the TNF and other transcription factors only. The predicted 
effects of TNF and its interaction with the transcription factors are displayed in a prediction 
Legend. Each interaction is supported by at least one literature reference, with dashed lines  
downregulated genes. Orange is the symbol of predicted activation while blue is the symbol 
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Prostate cancer is the most common cancer among men. From the statistical data 
collected by NIH between 2013 and 2015, about 11.2% of men in US will be diagnosed with 
prostate cancer at some point during their lifetime. In 2018, about 164,690 men are estimate to 
be newly diagnosed with prostate cancer. And it predicted to make up 9.5% of new cancer cases 
in 2018. Despite the high 5-year survival rate (about 98.2%) in prostate cancer, it remains the 
second leading cause of cancer death in men in the United States after lung and bronchus cancer. 
In 2018, prostate cancer contributes for 4.8% of all cancer death in US [1]. 
The most common treatment for prostate cancer including surgery, radiation therapy, 
hormone therapy and chemotherapy. Surgery is the most common therapy for localized prostate 
cancer with the side effects of bleeding, infections, cutting damage to the nearby tissues. 
Radiation therapy will be used when prostate cancer cells spread out of prostate gland or recurs 
occur after a surgery2. For others that has spread too far to be cured by radiation, hormone 
therapy and chemotherapy will be chosen, coming along with more severe side effects like high 
blood pressure, diarrhea, hair loss and fatigue [2]. But even after intensive multimodal therapy, 
the death rate of prostate cancer was more than 19.5 per 100,000 men per year based on 2011-
2015 NIH data. Reasons accounting for the lethality of advanced prostate cancer probably due 
to of its extreme genetic heterogeneity and the lack of effective therapeutic methods. [3]. In 
addition, the etiology and genetic determinants of prostate cancer remains largely 
unknown. The main goal of performing this study focusing on the function of piwi-
interacting RNAs in prostate cancer is to find potential therapeutic opportunities with 
less side effects in advanced prostate cancer treatment. 
Another focus of my research is piwi-interacting RNAs. Piwi-interaction RNAs, also 
known as piRNAs are a group of small non-coding RNAs expressed in animals [4]. It was first 
discovered in drosophila in 2006 [5-6] and got the name through their interaction with PIWI 
protein. PIWI protein is a subgroup of Argonaute family located within nuclear [7].  PIWI-
interacting RNAs have been shown to play a key role in maintenance of genomic stability in 
the germline [8]. Like miRNAs and siRNAs, piRNAs act as guides in sequence-specific gene 
regulation in conjunction with Argonaute proteins. But only piRNAs can interact with PIWI 
subfamily proteins. Furthermore, unlike siRNA and miRNA, the piRNA can silence gene 
expression at transcriptional level via DNA methylation [7]. This gives piRNAs some unique 
characteristics. The piRNA/PIWI complex can involve not only in epigenetic, but also in gene 
expression regulation [9] and DNA methylation [10]. Recent studies show that piRNAs  can be 
expressed in many other types of cells, including mouse brain, malignant and non-malignant 
somatic tissues [11], and human plasma, suggesting that piRNAs may have broader function 
than we expected. 
In human gene, more than 30,000 piRNAs have been identified, accounting for 9.5% 
of total gene [12-14]. Only a few of them has been thoroughly studied. Because of piRNAs’ 
large amount and various function involving in epigenetic, expression regelation and 
methylation, the role of piRNAs in human disease attracts people’s attention. It’s possible that 
piRNAs play a more important role in tumorigenesis, since the dysregulation of the PIWI–
piRNA system has been detected in tumor and certain somatic tissues [15]. A recent deep 
sequencing study suggests that piRNAs are expressed in both the breast tumor tissue and normal 
tissue. And four of them (piR-4987, piR-20365, piR-20485 and piR-20582) are significantly up 
regulated in tumor tissue compared with matched normal tissue [16]. Moreover, some of those 
piRNAs are related with cell cycle progression and the oncosuppressive estrogen receptor β in 
the following ingenuity pathway analysis [16]. Such result suggests that piRNAs are not only 
expressed in a wide range of tissues, but also play a key role in tumor regulation. 
A current study builds upon the previous association study conducted at Zhu lab. In 
that study, genotype and phenotype data for 4,700 African American subjects (2,275 cases and 
2,425 controls) were obtained from prostate cancer study in the Database of Genotypes and 
Phenotypes (dnGap). Then association analysis was performed to discover the piRNAs that 
were significantly related with prostate cancer. In conclusion, the variant rs61101785 (single 
nucleotide mutation A/C), located in piR-021163 appeared to be significant associated with 
prostate cancer (FDR-p-value=0.070). The minor allele frequency (MAF) of the variant (C 
allele) is 4.5% in cases and 2.6% in controls with an odds ratio of 1.63 (95% CI: 1.29-2.05), 
and is located at Chr4: 3,074,158. This means people carries rs61101785 variant have 0.63 
higher risk of prostate cancer than others in African American men. Moreover, this C mutation 
exist mostly in African American, but barely seen in Caucasian which might explain the 1.4 
times higher mortality rate and 0.6 times higher incidence rate in African American compared 
with Caucasian population. On the other hand, the wild type (A allele) may have some anti-
tumor effect. So minor allele (C allele) is referred as risk allele and wild type (A allele) is 
referred as protective allele. 
The former research on prostate cancer provided some evidences that the potential for 
a variant within a piRNAs to affect prostate cancer risk. To investigate the functional impact of 
the identified piR-021163 on prostate cancer, the study was designed. Specifically, we 
hypothesize that the A allele of piR-021163 have anti-tumor effect. Here, we test the hypothesis 
through in vitro assays, gene expression array and IPA analysis. 
 
Material and method 
1. Experimental cell lines and reagents 
Prostate cancer cell lines PC3, LNCap and normal prostate cell line WPMY-1 were 
purchased from ATCC (Manassas, VA). All the cell lines we used had past the ISO/IEC 
17025:2005 certified cell authentication testing prior to shipment. PC3, LNCap and WPMY-1 
cell lines were routinely cultured in Kaighn's Modification of Ham's F-12 Medium (Gibco) or 
ATCC-formulated Eagle's Minimum Essential Medium (ATCC) or Dulbecco’s Modified Eagle 
Medium (Gibco) with 10% heat inactive fetal bovine serum (Gemini bio-products) and 
100Units/ml penicillin and 100μg/ml streptomycin (Gibco) in a 5% CO2/95% air humidified 
incubator at 37℃. 
Single-stranded piR-021163 (A allele) mimics and single-stranded random RNA 
sequences of similar size (Table 1) used as negative controls were purchased from IDT (San, 
Jose, CA). PiR-021163 (A allele) and random RNA sequence were diluted with non-DEPC 
treated nuclease free water (AmericanBio) and stored in -20℃ for short term use and -80℃ for 
long term storage. 
Cell transfection was done through Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, 
CA) according to manufacturer’s protocol. 
2. Cell proliferation assay 
The impact of piR-021163 protective allele on the growth of prostate cancer cell lines 
(PC3 and LNCap) normal prostate cell line (WPMY-1) was evaluated through MTS assay. We 
used Cell Proliferation Assay (MTS) kit (Promega, Madison, WI) and followed the protocol 
provided by manufacturer. Briefly, 3,000 cells were seeded per well in 96-well plate 24 hours 
before transfection. Then, transfections of protective piR-021163 allele and negative control 
RNA will be carried out and cellular proliferation measurements will be performed starting on 
the day of the transfections (0h) and at 48h, 72h, and 96h post-transfection. In the measurement, 
10μl MTS reagent will added be directly into the 100μl cell culture media and incubate for 1.5 
hours at 37 Degrees celsiusstandard culture condition. Finally, the absorbance of MTS-stained 
cells will be quantified at 490 nm using a microplate spectrophotometer (Epoch, Biotek, 
Winooski, VT). Nine replicates are done for each treated condition and proliferation differences 
between groups are tested with Student’s t-test. 
3. Colony formation assay 
Colony formation assay is a way to measure the anchorage-independent growth in vitro 
which is crucial for carcinogenesis. In this part of research, 3,000 PC3 cells were seeded per 
well on a 6-well plate with 2ml complete F-12 medium. 24 hours after seeding, cells were 
transfected with either piR-021163 protective allele or negative control RNA. The 6-well plate 
were then incubated at 37 Degrees celsius standard culture condition for 2 weeks with the new 
completed medium added every 3 days to maintain cell growth. By the end of the second week, 
PC3 cell colonies were fixed with 80% alcohol for 15 minutes and stained with 0.04% crystal 
violet/2% ethanol. The anchorage-independent growth in piR-021163 and random control RNA 
treated cells will be calculated by colony counting under microscope. The comparison between 
piR-021163 and random control RNA was done by Student’s t test. All the experiment was 
done in triplicate. 
4. Wound healing assay 
Wound healing assay is a traditional in vitro technique to measure cancer cell migration 
and movement. Cell migration is the initial step in tumor metastasis, so it’s also a hallmark in 
tumor assessment. Seeding cells is still the start of this assay. About 500,000 cells were planted 
per well in a 6-well plate with 2ml complete medium. 24 hours after cell seeding, either piR-
021163 protective allele or negative control RNA were used for cell transfection. We used a 
100μl beveled filter tip to create a straight cell free scratch in the middle of cell culture plate 24 
hours after transfection.  We created this cell free gap to stimulate a wound between. To ensure 
the wound of piR-021163 treated group and random control RNA treated group was 
comparable, we used the same pipette tip in both group with similar angle and constant pressure. 
After wound was created, old complete medium was discarded and 2ml serum free medium 
was added in each well instead to suppress cell proliferation (we want to assess cell migration 
not cell growth). To quantify the healing progress, we photographed at 0h, 8h, 24h, 32h and 
48h after wound was created and measures the area of a wound in images with ImageJ v1.48 
software. The experiment was triplicated to rule out experimental bias. Student’s t test was also 
used to compare the wound healing difference between piR-021163 treated group and negative 
control RNA treated group. 
5. RNA extraction and reverse transcription 
PC3 cells were transfected with piR-021163 protective allele or negative control RNA 
24 hours before harvest. RNeasy Mini Kit (QIAGEN, Valencia, CA) was used to extract total 
RNA from treated cells. After extraction according to manufacturer’s protocol, the 
concentration and purity will be measured by the microplate spectrophotometer at 260nm and 
280nm. A 260/280 ratio range from 1.9 to 2.1 was accepted as pure RNA extract. The final 
RNA extracts were stored at -80 Degrees celsius for future use. 
After extraction, RNA solutions were diluted to 1ng/μl in non-DEPC treated nuclease 
free water for reverse transcription. Affinity Script Multi Temperature cDNA Synthesis Kit 
(Agilent Technologies, Santa Clara, CA) was used for reverse transcription. Product protocol 
was followed to ensure the accuracy. The final cDNA products were stored at -80℃ for further 
qPCR analysis. All samples were triplicated to avoid bias. 
6. Genome-wide expression profiling 
Epigenome-wide impact of the piRNA will be assessed using microarray analysis. We 
send biological triplicated RNA extract samples to Yale Center for Genome Analysis for 
microarray analysis on Affymetrix Clariom S Human Assay platform. The result will show 
gene expression level differences between piR-021163 protective allele and negative control 
RNA treated PC3 cells. Genes that have more than 1.5-fold change in expression affected by 
the piR-021163 were be further investigated for network and functional inter-relatedness using 
the Ingenuity Pathway Analysis (IPA) software tool (Ingenuity Systems, www.ingenuity.com). 
During the analysis, the Fisher's Exact Test is used to calculate a statistical significance of 
overlap of my gene with a particular functional annotation to find out the most related functional 
pathway. It is broadly adopted for functional study. Through Genome-wide expression profiling, 
relationships, mechanisms, functions, and pathways relevant to piR-021163 were revealed. 
 
Results 
1. Differential Effects of piR-021163 on cell proliferation in different cell lines 
Using MTS assay, the impact of piR-021163 protective allele on cell proliferation was 
tested in LNCap, PC3 and WPMY-1 cells. 
PiR-021163 and negative control RNA were diluted at 10μM, 0.1μM, 0.001μM to 
determine the effective dose in PC3 cell line (the final concentration in 96-well plate is 3*10-
2μM, 3*10-4μM and 3*10-6μM). RNA working concentrations were chosen based on the 
protocol of Lipofectamine RNAiMAX reagent where final concentration of 1*10-2μM was 
suggested for miRNA transfection. When administered at RNA concentrations ranging from 
0.001–10µM, piR-021163 protective allele can inhibit cell proliferation in PC3 cells in a dose- 
and time-dependent manner. 
We performed MTS testing at 48, 72, 96 hours after transfection. OD value from MTS 
assay can represent the number of living cells when tested. Using a standard curve, it can be 
transferred to cell number and come up with the representative growth curve across time (Figure 
1). At 10μM concentration, cells treated with piR-021163 showed significant less cell number 
(p-value=0.0065 at 48h, p-value=0.0003 at 72h, p-value=0.001 at 96h) suggesting piR-021163 
had induced a time-depend inhibition in PC3 cell proliferation. Cells exposed to other 
concentration of piR-021163 have no sign of inhibition (p-value all greater than 0.05 across 
time comparing with negative control group) compared with negative control group (treat with 
random RNA) which indicated that piR-021163’s impact on cell proliferation is dose-
dependent. The effective dose is 10μM. 
We also calculate the cell viability and inhibition ratio according to Equation 1 and 
Equation 2 where ODtreated is the OD value from piR-021163 in different concentration treated 
groups and ODNC is the OD value from negative control RNA treated group. The cell viability 
and inhibition ratio in all conditions after 48, 72, 96 hours of treatment are showed in Figure 2a 
and Table 2. Average inhibition rate is 36% at 48h, 48% at 72h and in increase to 51% at 96h.  
It confirms that only piR-021163 in 10μM concentration can efficiently inhibit cell proliferation 
to nearly 50% by 96 hours after transfection. Inhibition ratio grows constantly as time goes on, 
suggesting proliferate inhibition effect of piR-021163 in PC3 cells is also time-dependent. 
Cell viability =  × 100%                                                         (1) 
Inhibition ratio = 1 −   × 100%                                                   (2) 
Normal prostate cancer cell line WPMY-1 was used to test if piR-021163 have any side 
effects on cell proliferation in normal prostate tissue. No inhibition of cell proliferation was 
seen after 48, 72, 96 hours of 10μM piR-021163 transfection (inhibition rate for WPMY-1 at 
48h, 72h and 96h are all less than 5% with p-value greater than 0.05, Figure 2b). This prove 
that infection of piR-021163 have little adverse effect on normal prostate cells. 
However, when the effective dose was applied in LNCap, another commonly used 
prostate cancer cell line, no significant difference was observed compared with negative control 
group (Figure 3). The average inhibition rate is 3% at 48h, 6% at 72h and 13% at 96h comparing 
with negative control group with no pi-value less than 0.05. This result implies that LNCap 
cells are less sensitive to piR-021163 or maybe the mechanisms of piR-021163 inhibition effect 
in cell proliferation in different prostate cancer cell type are different. 
2. PiR-021163 plays a role in cancer cell anchorage-independent growth in 
PC3 cells 
Because inhibition of cell proliferation was only seen in PC3 cells, further invitro 
assays were done in PC3 cell line. 2 weeks after transfection with piR-021163 or negative 
control RNA, PC3 cell colonies were stained and counted. The photo of the colony formation 
experiment (Figure 3a) showed piR-021163 treated group have fewer colonies and smaller 
colony size. In addition, significant cell death was observed in piR-021163 treated group by 
day 5. This result was further confirmed with statistical analysis after colony calculation (Figure 
3b). There’s significant decline (p-value=9.913*10-10 in 2-tailed paired t-test) in colony number 
after treated with piR-021163 compared with negative control group suggested that piR-021163 
greatly limit anchorage-independent growth in PC3 cells. 
3. PiR-021163 plays a role in prostate cancer cell migration in PC3 cells 
Cancer cell migration was measured through wound healing assay. Digital images are 
recorded through microscope (Figure 4a) and the wound size (area of wound) data can be 
measured as function timing using ImageJ software. Comparing with negative control RNA 
group, piR-021163 significantly slow down the wound closure in PC3 cell 24 hours after 
creation of the straight wound (p-value=2.18*10-5). But cell size and morphology did not differ 
significantly in control and piR-021163 transfection group (p-value greater than 0.05). The 
difference between piR-021163 group and negative control group remain significant at 32h (p-
value=2.27*10-5) and 48h (p-value=5.188*10-4). 
Healing rate was calculated according to Equation 3 where Area0 stands for the wound 
area when wound was created and Areat is the wound area after t hours of wound creation. 
Statistical analysis of sound size data (Figure 4b) showed that the wound healing rate decrease 
from 80% to 58% at 48 hours when transfected with piR-021163 compared with negative 
control RNA. The significant decrease in wound healing rate indicates that piR-021163 also 
have impact on cancel cell migration defect. 
Healing rate = #$%&'(#$%&#$%&' × 100%                                                   (3) 
4. piR-021163 have influence on inflammation related functional pathways 
Based on the invitro experiment, we know that piR-021163 may have impact on cell 
proliferation, anchorage-independent growth and migration. So, total RNA was extracted 24 
hours after transfection of the piRNA in PC3 cells for microarray analysis to examine the impact 
of the genome-wide expression of this piRNA. Result of microarray showed that there are 70 
genes have 1.5-fold change between piR-021163 transfection and negative control RNA 
transfection group. About half of them are unexpressed in piR-021163-treated cells. 
IPA analysis then was applied on the 70 genes that express differently between 2 groups. 
IPA pathway analysis showed that piR-021163–affected genes were significantly enriched for 
those involved in apoptosis of tumor cells (p-value=3.33*10-3, z-score=0.600, Figure 5a), cell 
death of cancer cells (p-value=4.57*10-5, z-score=1.367, Figure 5b), and cell movement of 
cancer cells (p-value=1.15*10-4, z-score=-0.625, Figure 5c). It also showed that inflammatory 
response may be closely related with piR-021163 (p-value range from 4.01*10-3 to 3.52*10-
7). In the upstream and network analysis, a core functionally interrelated molecule, TNF, is 
revealed in piR-021163 functional pathway (Figure 6). As a well-known multifunctional 
cytokine secreted by inflammatory cells, TNF plays an important role in inflammation-
associated carcinogenesis as well as cell proliferation, death, necrosis and immune cell 
activation which is consistent with our in vitro findings [17,18]. 
 
Discussion 
Although an expanding body of evidence suggests that piRNAs may have broad 
function in cell cycle, gene expression regulation and DNA methylation, not much attention 
has paid on the molecular mechanisms through which piRNAs act to modulate cell growth in 
the prostate cancer are poorly understood. Our study aimed at finding out potential mechanisms 
of piR-021163 action in prostate cancer cells. 
In our analysis of piR-021163 function in prostate cancer, we found that it has different 
impact on different prostate cancer cell lines. Significant inhibition in cancer cell proliferation 
can be seen in PC3 cells but not LNCap cells. I think that’s because PC3 cell line is more 
aggressive than LNCap. Although both cell lines are commonly used cell lines derived from 
metastatic lesions, PC3 was derived from bone but LNCap was derived from lymph node. PC3 
was establish from grade IV adenocarcinoma that can’t respond to androgens, glucocorticoids 
or fibroblast growth factors, but can be influenced by epidermal growth factors [19]. On the 
contrast, LNCap can synthesis of prostate-specific antigen, respond to androgens and have 
relatively low metastatic potential compared with PC3 cells. A study also proved that PC3 and 
LNCap cells are different in the expression of basal cell markers [20]. PC3 can express seven 
basal cell markers (CD49b, CD49f, CD55, CD59, CD99R, CD104 and CD44) but LNCap can 
only express three (CD49f, CD59, and CD99R) [20]. Basal cell markers will be expressed by 
cancer cells as disease worsens. So, PC3 is considered to represent more progressed cancer 
subtypes than LNCaP which might can help explain why PC3 is more sensitive to piR-021163 
transfection. The different result in different prostate cancer cell lines suggested that the role of 
piR-021163 in prostate cancer development and progression may be cancer subtype-specific.  
It also indicates that our piRNA can help treat with metastatic prostate cancer that is resistant 
to hormone therapy subsequently developed an aggressive prostate cancer subtype and has a 5-
year survival rate of 35% [21]. 
Besides the inhibition effect on cell proliferation, inhibition was also observed in cell 
anchorage-independent growth and cell migration after transfection of piR-021163 in PC3 cells 
which suggested its potential in prostate cancer treatment. That conclusion from invitro 
experiment was then confirmed with the network analysis that piR-021163 involved in 
apoptosis of tumor cell, cell death of cancer cells, and cell movement of cancer cells.  
In addition, TNF was revealed as a core of functionally interrelated molecules in the 
IPA upstream analysis. According to the IPA analysis, TNF is predicted to be activate by piR-
021163 transfection. TNF gene is predicted to be 3.058 times upregulated after transfecting 
with piR-021163 in PC3 cells through upstream analysis. This gene is a protein coding gen that 
encodes multiple cytokines that belongs to TNF super family including TNF-α, a well-known 
inflammatory cytokine produced by macrophages during acute inflammation [25]. This 
cytokine is also crucial in resistance to infection and cancers. It can activate multiple signal 
transduction pathways by binding with the receptors (TNFR1 and TNFR2) and induce 
apoptosis to cells [26]. 
Besides the activation of TNF, piR-021163 transfection can also result in the inhibition 
of inflammation of body cavity which is very reasonable in the piR-021163 function of 
inhibiting development of prostate cancer. 
It’s commonly agreed that chronic inflammation contributes to the onset and 
development of cancer in human. In prostate cancer, inflammation may also be a protentional 
risk factor. Multiple evidence from former studies suggested that inflammation is very common 
within the adult prostate. In a result of from the baseline data of the REDUCE (REduction by 
DUtasteride of prostate Cancer Events) trial, about 80% of prostate cancer patients showed 
some inflammation in their biopsies [22] which suggested the significant correlation between 
inflammation and prostate cancer. A previous meta-analysis using data from 11 case-control 
studies found that there’s an increased risk of prostate cancer among men with prior prostatitis 
[23]. Biological mechanisms studies found out that the chronic inflammation is linked to 
prostate cancer metastasis through angiogenesis and epithelial mesenchymal transition (EMT), 
impacting the dynamics of the tumor microenvironment [24]. All the conclusion from former 
papers supports out result from IPA that piR-021163 can inhibit inflammation of body cavity 
which may result in the inhibition of prostate cancer progress. 
IPA’s result on the regulator effect the upstream active of TNF may indirectly 
correlated with the inhibition of inflammation. From Figure 6a, we know that the activation of 
TNF can increase the expression of CXCL8, HMOX1, ZFP36, DUSP1, LGALS9, CCL20, 
PTGS2, BIRC3 and reduce the expression of NR0B2, CEBPA, SPARC gene. Those gene 
expression changes also have indirect interaction with the inhibition of inflammation in body 
cavity. The indirect connection between TNF and inflammation suggests that not only can TNF 
activation directly inhibit prostate cancer development through TNF signaling pathway, but 
TNF also can indirectly suppress prostate cancer development through the inhibition of 
inflammation.  
With the result of IPA analysis and former research of TNF and inflammation on 
prostate cancer, we can conclude that TNF is the key mediator that can contributive to the 
inhibition of inflammation and protective against prostate tumorigenesis. Given that chronic 
inflammation contributes to the metastasis and development of prostate cancer through tumor 
microenvironment, our study implies that piR-021163 can protect against prostate cancer 




In conclusion, our work finds out that piR-021163 can inhibit prostate cancer cell 
proliferation, migration and anchorage-independent growth. But the result is unified in all 
prostate cancer cell lines. The cancer suppression effect of piR-021163 might mediate through 
the activation TNF and is related with the inhibition of inflammation. 
 Our work on the function of piRNAs in cancer is only a beginning. The effect of 
ipR-021163 in suppressing prostate cancer development need to be confirmed with further 
animal experiment. Moreover, qPCR and western blot can also help us to understand what’s 
the potential reasons for disparities function that piR-021163 plays in different prostate cancer 
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